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Purpose or Objective: Neoadjuvant chemoradiotherapy 
(CRT) is considered a standard approach for locally invasive 
rectal cancer. Several phase 3 studies have shown an 
improvement in local control with combined radiotherapy 
and capecitabine / 5-fluorouracil. There is good evidence 
that increased dose of radiotherapy is associated with both 
better pathological response and survival in many 
malignancies, although the data in rectal cancer is less 
convincing. In this study we assessed the impact of dose-
escalated radiotherapy on pathological outcome. 
 
Material and Methods: We evaluated all patients who 
received chemo-radiotherapy for rectal cancer and 
subsequently had an anterior resection/ abdominoperineal 
resection with a total mesorectal excision (TME) between 
February 2012 and December 2014. Patients received 50.4Gy 
1.8Gy fractions, and more recently those who have T3/4 
disease with a threatened circumferential margin had a 
simultaneous integrated boost of the primary tumour to a 
total dose of 53.2Gy, with concurrent capecitabine 
chemotherapy (825mg/m2 BD) daily throughout treatment. 
Treatment was initially using 3-D conformal radiotherapy but 
more recently has been using a VMAT technique with cone 
beam CT used during treatment. Surgery was performed 8-12 
weeks after completion of CRT.The primary end point was 
pathological response (Dworak score 0-4) of the operative 
specimen. Scores of 0-2 were considered to be non-
pathological responders and scores of 3-4 were considered to 
be pathological responders. 
 
Results: A total of 73 patients received neoadjuvant 
chemoradiotherapy. 61 patients weretreated with a standard 
radiotherapy fractionation of 50.4Gy in 28 fractions (Group A) 
and 12 patients were treated with a dose escalated 
fractionation to the primary tumour of 53.2Gy in 28 fractions 
(Group B). The rate of pathological response was 39.3% in 
Group A and 86.7% with Group B (t=3.55, p<0.001). 
 
Conclusion: This study demonstrates the beneficial effects of 
dose-escalated radiotherapy and wetherefore recommend 
this regime be considered for inclusion in future phase 2 
studies. 
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Purpose or Objective: Early proctoscopy (1 year) can predict 
late rectal mucosa changes and therefore can be used as 
surrogate end-point for late rectal toxicity. The aim of this 
study was to retrospectively analyze data of patients treated 
at a single institution, consecutively enrolled in different 
prospective clinical trials, trying to determine a correlation 
between treatment parameters and VRS (Vienna Rectoscopy 
Score) recorded at 1-year proctoscopy. 
 
Material and Methods: Patients with prostate 
adenocarcinoma treated with curative or adjuvant RT 
underwent endoscopy one year after RT; 195 patients were 
included in this analysis. Correlations between VRS > 2 and 
several treatment parameters were investigated by 
univariate and multivariate logistic analysis. 
 
Results: Patients treated with an EQD2 dose > 75 Gy, with 
hypofractionatied schedule and radiosurgery boost had a 
higher incidence of VRS > 2 (p= < 0.001). On the contrary, 
previous surgery and 3D-conformal radiotherapy (vs IMRT) 
were associated with a lower incidence of rectal mucosal 
changes (p=< 0.001; p= 0.003, respectively). At multivariate 
analysis radiosurgery boost was associated with the highest 
odd ratios for the risk of developing a VRS > 2 (OR: 4.143; CI: 
1.24-13.81; p=0.001). Even surgery showed a significant 
correlation with VRS > 2 (OR: 0.39; CI: 0.17-9.94; p=0.037, 
Table 1). 
 
 
 
Conclusion: Prolonged patients follow-up is needed to 
“clinically” confirm the increased rectal toxicity produced by 
radiosurgery boost. 
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Purpose or Objective: The objective of the study is to 
determine the correlations among the variables of dose and 
the sphincter function (SF) in patients with locally advanced 
rectal cancer treated with preoperative 
capecitabine/radiotherapy followed by Local Anterior 
Resection(LAR) +TME. 
 
Material and Methods: We have retrospectively reviewed 92 
consecutive patients with LARC treated at our center with 
LAR from 2006 and more than 1 year free from disease. We 
re-contoured the anal sphincters (AS) of patients with the 
help of the radiologist. SF was assessed with the Wexner 
scale (0-20 points, being punctuation inversely proportional 
to SF). All questionnaires were filled out between January 
2010 and December 2012. Dosimetric parameters that have 
been studied include: V20 V30, V40, V50, mean dose 
(Dmean), mínimum dose (Dmin), D90 (dose received by 90% 
of the sphincter) and D98 Statistical analysis: the correlations 
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among the variables of dose and SF were studied by the 
Spearman correlation coefficient. Differences in SF related to 
maximum doses to the sphincter were assesed by the Mann-
Whitney test. 
 
Results: Wexner scaleMean Wexner score was 5.5 points 
higher in those patients with V20>0 compared to those for 
which V20=0 (p=0.008). In a multivariate regression model, 
results suggest that the effect of V20 on poor anal sphincter 
control is independent of the effect of distance, with an 
adjusted OR of 3.42 (1.09, 10.72). 
 
Conclusion: In order to improve the SF, the maximum dose of 
radiation to the AS should be limited, when possible, to < 20 
Gy 
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Purpose or Objective: Anal cancer is a relatively rare 
cancer, making up approximately 0.4% of all new diagnoses of 
cancer. In 2011, there were 1,175 new cases of anal cancer 
diagnosed in the UK. The current standard treatment is 
radical chemoradiotherapy. We conducted a retrospective 
case series of anal squamous cell carcinoma treated in the 
regional radiation oncology network between 2008 and 2014 
inclusive to examine recent management practice and 
outcome of anal squamous cell carcinoma.  
 
Material and Methods: Patients were identified from the 
regional radiation oncology cancer database. Data was 
collected retrospectively from ARIA® oncology information 
system and patient charts. Information was collected in 
relation to demographic details, radiotherapy dose and 
regimen, chemotherapy regimen, persistence and recurrence 
of disease, salvage surgery rates, and survival analysis. 
Statistical analyses were carried out using IBM® SPSS® 
statistical software version 21.0. 
 
Results: 79 cases of anal squamous cell carcinoma were 
identified. Mean age at commencement of radiotherapy was 
60.2 years (+/-13.2 years). 29 patients were male (36.7%) and 
50 (63.3%) were female. 8 (10.1%) patients had documented 
HIV infection. 74 (93.7%) patients were treated with radical 
chemoradiotherapy. The most common total radiotherapy 
dose delivered was 50.4 Gy in 28 fractions (N=58; 73.4%) (see 
table 1). The majority of patients (N=67; 84.8%) received 
combination chemotherapy with mitomycin C and 5-FU. 2 
(2.5%) patients who received radical treatment had 
persistent disease following radiotherapy. 5 (6.3%) patients 
had loco-regional recurrence and 3 (3.8%) patients developed 
solid organ metastases following complete treatment 
response at the primary. 4 patients had salvage surgery. 
Survival was measured from the initiation of radiotherapy 
treatment using the Kaplan–Meier method. Overall survival 
was 98%, 90%, 83% and 83% at 1, 2, 3 and 4 years 
respectively. Disease free survival was 91%, 77%, 74% and 74% 
at 1, 2, 3 and 4 years respectively (see fig. 1). 
 
 
 
 
 
Conclusion: Our study found that the majority of patients in 
our radiation oncology network were treated with 
chemoradiotherapy in line with international guidelines. In 
our study, chemoradiotherapy in the treatment of anal 
squamous cell carcinoma was associated with a high 
complete response rate and a low treatment failure rate. 
Treatment and outcomes in our study are consistent with 
international trial data. 
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Purpose or Objective: Concurrent chemoradiotherapy (CRT) 
is the standard treatment for locally advanced rectal cancer 
to downstage disease prior to definitive surgery. Previous 
studies report ≥ grade 3 (G3) bowel toxicity of 3 -4%; 
QUANTEC recommend small bowel V45 <195 cm3 to reduce 
G3 toxicity. We noted an increase in G3 bowel toxicity in the 
period Sept – Dec 2014 in our institution and aimed to 
determine the cause.  
 
Material and Methods: We retrospectively identified patients 
who received pre-operative long-course CRT for rectal cancer 
between Sept – Dec 2014 and Jan - April 2014 (control), and 
reviewed case notes and radiotherapy (XRT) plans. Small 
bowel V45 was calculated for each patient. G3 toxicity was 
defined as per the CTCAE grading system for diarrhoea, 
abdominal pain and vomiting.  
 
Results: Fifty patients were identified: Jan – April cohort 
(n=28) was compared to Sept – Dec cohort (n=22). Both 
groups were similar for patient demographics, CRT treatment 
volumes and doses, patient positioning and XRT delivery 
technique. Two of 28 patients (9%) in Jan – April cohort had 
G3 bowel toxicity; both were admitted for symptom control. 
Six of 22 patients (27%) in Sept – Dec cohort developed G3 
bowel toxicity; 5 (23%) required admission.  
G3 toxicity occurred after a minimum of 16 fractions (range 
16-21). All patients had normal bowel function prior to 
